SecBot SecBot
PRESS-RELEASE ·Filed Jun 15, 2026

OPK

OPKO Health, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor for next clinical milestones such as IND filing or Phase 1 initiation. The preclinical data supports the platform but is early-stage; stock movement likely limited until human data is available.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.40
T+0 close · Jun 15, 2026 · via day close
Latest settled
+10.00%
T+60 · $1.54
Vs SPY
+9.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $1.40entry
  2. T+1 · 5mo ago −0.71%α −0.12% · $1.39
  3. T+5 · 5mo ago +2.14%α +3.53% · $1.43
  4. T+20 · 4mo ago −12.14%α −11.39% · $1.23
  5. T+60 · 2mo ago +10.00%α +9.00% · $1.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

OPKO Health presented preclinical data for OPK8801001, a long-acting hGH receptor antagonist for acromegaly, at ENDO 2026. In vitro data showed 20-fold greater potency than Pegvisomant, and in vivo data demonstrated dose-dependent IGF-1 suppression, suggesting potential for weekly dosing. However, these are early preclinical results with no clinical or regulatory milestones, limiting near-term impact.

Key Facts

  • OPK8801001 is a novel long-acting hGH receptor antagonist for acromegaly.
  • In vitro data showed approximately 20-fold greater potency than Pegvisomant.
  • In vivo data demonstrated robust, dose-dependent, sustained suppression of IGF-1.
  • Preclinical findings suggest potential for a once-weekly treatment alternative to daily therapies.
  • Data presented at ENDO 2026, the Endocrine Society's annual meeting.

Financial Impact

No financial data provided; preclinical stage with no revenue impact.

Risk Factors

  • Preclinical results may not translate to clinical efficacy or safety.
  • Competition from existing acromegaly therapies (e.g., Pegvisomant, somatostatin analogs).
  • Regulatory and development risks for a novel biologic candidate.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311726

US Market Status

Market Closed · Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026